射血分数保留与降低心衰患者的预后及NT-proBNP
本研究纳入因急性失代偿性心衰住院的患者,按左室射血分数分为HFpEF(≥50%,n=283)和HFrEF(<40%,n=776),评估出院时NT-proBNP绝对值和百分比变化对出院后6个月全因死亡的预后价值。结果显示出院NT-proBNP水平及降幅在两种心衰中预测死亡风险相似,且低NT-proBNP出院时HFpEF患者合并症更多。
要点
- 出院NT-proBNP水平在HFpEF与HFrEF中预测6个月全因死亡风险相似。
- NT-proBNP降幅≤30%或>30%-60%者死亡风险均高于降幅>60%者。
- 低NT-proBNP(≤3000 pg/mL)出院时HFpEF患者合并症更多。
核心结论
- NT-proBNP在HFpEF与HFrEF中提供相似的相对风险信息。
- 低NT-proBNP水平的HFpEF患者合并症对预后的相对贡献可能更大。
研究设计与样本
- 回顾性队列分析?原文未明确设计类型,仅提及按LVEF分组并采用多变量校正Cox回归。
- HFpEF组n=283(LVEF≥50%),HFrEF组n=776(LVEF<40%)。
- 评估出院NT-proBNP绝对值和百分比变化对出院后6个月全因死亡的预后价值。
主要发现
- NT-proBNP每增加2.7倍,HFpEF死亡HR为2.14(95%CI 1.48-3.09),HFrEF为1.96(95%CI 1.60-2.40)。
- 与NT-proBNP降幅>60%相比,降幅≤30%者HFpEF死亡HR 4.60(95%CI 1.47-14.40),HFrEF HR 3.36(95%CI 1.93-5.85)。
- 降幅>30%-60%者HFpEF死亡HR 3.28(95%CI 1.07-10.12),HFrEF HR 1.79(95%CI 0.99-3.26)。
- 低NT-proBNP(≤3000 pg/mL)出院时HFpEF患者合并症更多,高NT-proBNP(>3000 pg/mL)时无此差异。
临床怎么用
- 出院NT-proBNP水平可用于HFpEF和HFrEF患者的死亡风险分层。
- NT-proBNP降幅≤60%提示死亡风险增高,需加强随访。
- 低NT-proBNP的HFpEF患者应重视合并症管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We assessed the prognostic significance of absolute and percentage change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients hospitalised for acute decompensated heart failure with preservedejection fraction (HFpEF) versus heart failure with reduced ejection fraction (HFrEF). METHODS: Patients with left ventricular ejection fraction ≥50% were categorised as HFpEF (n=283), while those with <40% as were categorised as HFrEF (n=776). Prognostic values of absolute and percentage change in NT-proBNP levels for 6 months all-cause mortality after discharge were assessed separately in patients with HFpEF and HFrEF by multivariable adjusted Cox regression analysis. Comorbidities were compared between heart failure groups. RESULTS: Discharge NT-proBNP levels predicted outcome similarly in HFpEF and HFrEF: for any 2.7-factor increase in NT-proBNP levels, the HR for mortality was 2.14 for HFpEF (95% CI 1.48 to 3.09) and 1.96 for HFrEF (95% CI 1.60 to 2.40). Mortality prediction was equally possible for NT-proBNP reduction of ≤30% (HR 4.60, 95% CI 1.47 to 14.40 and HR 3.36, 95% CI 1.93 to 5.85 for HFpEF and HFrEF, respectively) and for >30%-60% (HR 3.28, 95% CI 1.07 to 10.12 and HR 1.79, 95% CI 0.99 to 3.26, respectively), compared with mortality in the reference groups of >60% reductions in NT-proBNP levels. Prognostically relevant comorbidities were more often present in patients with HFpEF than patients with HFrEF in low (≤3000 pg/mL) but not in high (>3000 pg/mL) NT-proBNP discharge categories. CONCLUSIONS: Our study highlights-after demonstrating that NT-proBNP levels confer the same relative risk information in HFpEF as in HFrEF-the possibility that comorbidities contribute relatively more to prognosis in patients with HFpEF with lower NT-proBNP levels than in patients with HFrEF.
引用
- Salah K, Stienen S, Pinto YM, et al. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. Heart. 2019. PMID: 30962192. doi:10.1136/heartjnl-2018-314173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。